NASDAQ:MTCR

Metacrine, Inc.

Stock

USD

Market Cap

25.48M

Beta: −0.74

PE Ratio

−0.98

PFCF: −1.05

Dividend Yield

99.76%

Payout:0%

Overview Financials Filings people Ownership API Chart Data

locale
United States
market
STOCKS
industry
Biotechnology
website
www.metacrine.com
ipo date
Sep 16, 2020

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Excel Tearsheet

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

*Estimate based on analyst consensus